Italy, July 8 -- The European Investment Bank (EIB) has signed a €150 million loan agreement with Alfasigma, a global pharmaceutical company founded in Italy, whose products are present in more than 100 markets worldwide.The agreement, announced today by EIB Vice-President Gelsomina Vigliotti and Alfasigma's Chief Financial Officer Tatiana Simonelli, will support the development of breakthrough therapies in the areas of rare diseases and specialty care. The EIB financing aims to support Alfasigma's R&D activities over the three-year period from 2025 to 2027, focusing on new treatments in gastroenterology and hepatology, vascular medicine, and rheumatology. It will help accelerate the translation of scientific advances into patient-cen...